Omrix公司推出新型外科密封剂

2005年1月公布的新纤维蛋白密封剂使用指南中，在标准手术方案效果不佳的时候，一种人体外科密封剂被批准用于提高止血效果。

这种密封剂叫做Quixil，以前只在肝脏手术和大关节置换的时候使用，因为其作用效果得到了证实。在传统的纤维蛋白密封剂中，使用了来自牛的蛋白质。 但是，Quixil是唯一的没有动物来源成份的密封剂。这种密封剂在融化后1分钟之内就可以使用，比传统的纤维蛋白黏附性更强更柔软，即使在低温条件下也是如此，并能够降低败血症的发生率。

这种两种成分的密封剂包含两种生物活性成份（BAC）--人凝结蛋白和tranexamic酸--和凝血酶。每一种成份在制造过程中都有两种独立的和不同的病毒激活和清除步骤，以减少非包膜病毒传播的危险。这也增加了灭活尚未被鉴别病原的几率。

Quixil是Omrix生物制药公司的注册商标，在英国是由Johnson & Johnson公司推向市场的。
 
Extended Indications for Surgical Sealant

Following the publication of new fibrin sealant guidelines in January 2005, a human surgical sealant is now approved for use in improving hemostasis, where standard surgical techniques are insufficient.

Called Quixil, the sealant was previously only indicated for liver surgery and large-joint replacement where efficacy has been proven. In traditional fibrin sealants, bovine sourced proteins are present. Quixil, however, is the only sealant that is completely free of animal-sourced components. The sealant is ready for application in less than one minute after thawing and is more adherent and flexible than traditional fibrin sealants, even at low temperatures, potentially lowering sepsis rates.

The two-component sealant consists of a biologic active component (BAC)--human clottable protein and tranexamic acid--and thrombin. Each of the components undergoes two separate and different virus activation and removal steps during manufacturing to reduce the risk of transmission of non-enveloped viruses. This also increases the probability of inactivating unidentified pathogens.

Quixil is a registered trademark of Omrix Biopharmaceuticals, S.A. (Brussels, Belgium) and is marketed in the United Kingdom by Johnson & Johnson Wound Management (New Brunswick, NJ, USA).